@article {7880,
	title = {Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer},
	journal = {Urology},
	volume = {71},
	year = {2008},
	note = {Cited By :2Export Date: 21 February 2017},
	month = {2008},
	pages = {1181 - 1185},
	abstract = {Objectives: Docetaxel is an effective first-line treatment for hormone-refractory prostate cancer. Nevertheless, the prognosis subsequent to progression after first-line therapy is poor and no second-line treatment has been established. Methods: A total of 34 patients with androgen-independent prostate cancer received doxorubicin, 30 mg/m2, every 2 weeks and ketoconazole daily, 400 mg orally every 8 hours. All patients had been treated with docetaxel and had disease progression within 6 months after completion of first-line treatment. Results: Of the 32 evaluable patients, 13 (43.7\%, 95\% confidence interval [CI] 26.3\% to 62.3\%) had a prostate-specific antigen (PSA) response, and 4 (28\%, 95\% CI 8.4\% to 58.1\%) of 14 patients with measurable disease had a response to therapy. The median time to progression (TTP) was 3.9 months (95\% CI 2.0 to 5.9), and the median overall survival (OS) was 13 months (95\% CI 8.7 to 17.3). Toxicity was mild, with only 4 cases of nonhematologic grade 3 or 4 toxicity. The most frequent toxicity was nail changes (33 of 34 patients), which was mainly grade 1 (30 cases). Conclusions: The combination of biweekly doxorubicin and ketoconazole is an effective, well-tolerated, second-line therapy for hormone-refractory prostate cancer. {\textcopyright} 2008 Elsevier Inc. All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-44649119833\&doi=10.1016\%2fj.urology.2008.02.048\&partnerID=40\&md5=3607879510ab20fe5d14f0eb80e6ffd3},
	author = {Lainakis, G. and Nikos, A. and Gerassimos, A. and Michael, C. and Iraklis, M. and Konstantinos, L. and Ioannis, V. and Harilaos, K. and Dimopoulos, M.A. and Bamias, A.}
}
